SHOC2 and cancer: These and previous results agree with the data from cancer functional screens and suggest that, in RAS–GTP-locking conditions, such as those resulting from oncogenic mutations, canonical RAS proteins can substitute for MRAS within the SHOC2–PP1C complex.